Long-Term Outcomes of HCV-Related Cryoglobulinemia Vasculitis Treated with Direct-Acting Antiviral Agents

Recent studies demonstrate that direct-acting antiviral agents (DAAs) are safe and effective at eradicating hepatitis C virus (HCV)–related cryoglobulinemia vasculitis, with short-term evidence of cryoglobulin clearance. However, it is unclear how durable the response is.

Long-term outcomes were measured in a prospective, international, multicenter cohort study involving 146 patients with HCV-related cryoglobulinemia vasculitis treated with standard combinations of DAAs for 12 or 24 weeks. Median follow-up was 15.3 months. The primary endpoint was clinical response of cryoglobulinemia vasculitis. Responses were defined as complete when there was improvement in all organs affected at baseline and as partial when there was improvement in only …